GC34015
MRE-269 (ACT-333679)
Also known as 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid
MRE-269 (ACT-333679) is an active metabolite of selexipag, and acts as a selective IP receptor agonist
ChemicalCAS475085-57-5MW419.52FormulaC25H29N3O3
- CAS number
- 475085-57-5
- Molecular weight
- 419.52
- Formula
- C25H29N3O3
- Solubility
- DMSO ： ≥ 50 mg/mL (119·18 mM);Water ： ＜ 0·1 mg/mL (insoluble)
- InChIKey
- OJQMKCBWYCWFPU-UHFFFAOYSA-N
- Catalogue number
- GC34015
- Brand
- GLPBIO
Computed properties PubChem CID 9931891 · XLogP 4.5 · TPSA 75.6 Ų · H-bond donors 1
- XLogP
- 4.5
- TPSA
- 75.6 Ų
- H-bond donors
- 1
- H-bond acceptors
- 6
- Rotatable bonds
- 11
- Heavy atoms
- 31
SMILES CC(C)N(CCCCOCC(=O)O)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
Computed descriptors from PubChem (CID 9931891), public domain. Identity cross-checked against the supplier's molecular formula and weight — verify before use.
Ordering in Israel
- Lead time
- Ships from the manufacturer to your lab in 8–14 business days; customs and cold chain handled by LABO Scientific.
- Pricing
- Quoted in ILS, excl. VAT. Add the item to your quote and we confirm the final price, usually the same business day.
- Documents
- Lot certificate of analysis and manufacturer SDS are emailed with your order confirmation.
- Who we serve
- Universities, hospitals and biotech companies across Israel. Research use only — not for diagnostic or therapeutic use.
- Questions
- WhatsApp · +972-55-990-7576 · orders@labo.co.il